Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 known ✓ | O15379 | 2/20 | 0.48 |
| ▸ | HDAC1 known ✓ | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC2 known ✓ | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC10 known ✓ | Q969S8 | 2/20 | 0.48 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 2/20 | 0.48 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 2/20 | 0.48 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.46 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18703895 | 1.00 | EPHX2 (0.55) | EPHX2MMP2HDAC3HDAC1HDAC2 | |
| SCHEMBL17599911 | 0.99 | EPHX2 (0.56) | EPHX2MMP2HDAC3HDAC1HDAC2 | |
| SCHEMBL18703881 | 0.99 | EPHX2 (0.56) | EPHX2MMP2HDAC3HDAC1HDAC2 | |
| SCHEMBL7452946 | 0.99 | EPHX2 (0.56) | EPHX2MMP2HDAC3HDAC1HDAC2 | |
| SCHEMBL17767806 | 0.92 | EPHX2 (0.61) | EPHX2HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL17767811 | 0.92 | EPHX2 (0.61) | EPHX2HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL7301925 | 0.91 | MMP2 (0.52) | EPHX2MMP2HDAC3HDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL23748118 | 0.88 | HDAC3 (0.49) | EPHX2HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL28090584 | 0.88 | EPHX2 (0.58) | EPHX2HDAC3HDAC1HDAC2HDAC10 | |
| Hydrochloric Acid SCHEMBL21373253 | 0.88 | ALDH1A1 (0.54) | EPHX2MMP2LMNAHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11014966-B2 | Compounds and therapeutics uses thereof | CENTUARI THERAPEUTICS LIMITED (GB) | 2021-05-25 | — | — | US | disclosed |
| US-20210085798-A1 | IMMUNITY LINKER MOLECULES AND THEIR USE IN THE TREATMENT OF INFECTIOUS DISEASES | CENTAURI THERAPEUTICS LIMITED (GB) | 2021-03-25 | — | — | US | disclosed |
| EP-3765155-A1 | IMMUNITY LINKER MOLECULES AND THEIR USE IN THE TREATMENT OF INFECTIOUS DISEASES | Centauri Therapeutics Limited (GB) | 2021-01-20 | — | — | EP | disclosed |
| EP-3512544-B1 | PEPTIDE COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTAURI THERAPEUTICS LTD (GB) | 2020-10-28 | — | — | EP | disclosed |
| WO-2019175590-A1 | IMMUNITY LINKER MOLECULES AND THEIR USE IN THE TREATMENT OF INFECTIOUS DISEASES | CENTAURI THERAPEUTICS LIMITED (GB) | 2019-09-19 | — | — | WO | disclosed |
| US-20190248838-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2019-08-15 | — | — | US | disclosed |
| EP-3512544-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | Centauri Therapeutics Limited (GB) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018051085-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTAURI THERAPEUTICS LIMITED (GB) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248838-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | MAVS, MYD88, CD47 | HDAC3 2490/4885HDAC1 2536/4885HDAC2 2537/4885 |
| US-11014966-B2 | Compounds and therapeutics uses thereof | MYD88, MAVS, CD47 | HDAC3 2474/4885HDAC1 2666/4885HDAC2 2633/4885 |
| US-20210085798-A1 | IMMUNITY LINKER MOLECULES AND THEIR USE IN THE TREATMENT OF INFECTIOUS DISEASES | MYD88, MAVS, TLR3 | HDAC3 2228/4885HDAC1 2613/4885HDAC2 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.